DelNova, Inc. is a biopharmaceutical company focused on addressing unmet medical needs. DelNova is resolving complications arising from botulinum toxin therapies (eg. Botox®). The first product under development, ReViVox™ is based on a clinically validated drug currently approved for a different medical use and route of administration. The novel formulation will manage undesirable side effects resulting from neurotoxin injections in both medical and cosmetic applications.
Richard Lehman, MD does not let moss grow under his feet. As you will hear in this episode, he is involved in the whole...
RiskLD is a physician-led startup out of Cleveland focused on improving maternity outcomes.
Bryan Campbell leads the Colorado Medical Society and started of his mission going back to the fundamental question of why CMS exists. How can...
